AGMAT

Across TCGA pan-cancer cohorts, AGMAT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGMAT data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AGMAT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AGMAT expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where AGMAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.537	0.284	<.001	73	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	24	view →
GBM	DFS	Quartile	All	0.443	0.251	.008	20	view →
UCEC	DFS	Tertile	III,IV	1.000	0.364	.016	16	view →
HNSC	DFS	Quartile	II,III,IV	0.787	0.453	.007	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AGMAT–PDAC (DFS)

Open the PDAC breakdown →